Pharmaceutical Benefits Scheme: Takhzyro approved for hereditary angioedema patients in Australia


Reprieve for Australians who suffer rare and deadly genetic condition as a $241,000-a-year medicine is listed on the pharmaceutical benefits scheme  

  • Expensive angioedema medicine to be listed on Australian government scheme 
  • Pharmaceutical Benefits Scheme slashes the price of important medicines 
  • Patients will now pay $41.30 per script rather than $241,000, Greg Hunt says 










Health Minister Greg Hunt announced the listing in a statement on Sunday

Health Minister Greg Hunt announced the listing in a statement on Sunday

From next month a medication for a rare and potentially deadly genetic condition with be available to Australians through the Pharmaceutical Benefits Scheme.

The federal government has listed the medicine Takhzyro for patients with hereditary angioedema, a condition that occurs in around one in 50,000 people.

Angioedema results from a defect in the gene that controls a blood protein called C1-inhibitor.

It leads to higher levels of a substance called bradykinin in the bloodstream, which causes symptoms such as swelling and pain.

Health Minister Greg Hunt said the new listing would benefit more than 100 Australians each year.

‘Without this PBS subsidy, Australian patients are paying around $241,000 per year for this treatment,’ Mr Hunt said in a statement on Sunday.

‘From December 1, they’ll pay $41.30 per script or $6.60 with a concession card.’

Advertisement



Source link

Spread the love

Written by bourbiza

Football fans donate kit for disadvantaged kids’ Christmas presents

Meghan Markle’s father calls for Duchess of Sussex to be stripped of her royal title